The presence of AR-GSRs in clinical prostate cancer has not been described by previous large-scale tumour genomic profiling studies, probably because these studies have employed copy number arrays, whole-exome sequencing or moderate-coverage whole-genome sequencing, which are not powered for robust structural variant discovery in a high repeat-content gene such as AR1, 2, 3, 4, 5. This evidence concerns the gene TCF20 and neoplasm.